A biotech firm developing adult stem cell therapies for conditions like erectile dysfunction, back pain, and stroke, with no approved products yet.
No revenue recorded in annual data; operating losses around USD 0.01B each year, funded by investors rather than sales.
No approved products or revenue, so competitors like Mesoblast and Athersys could dominate the stem cell space first. Moat is weak because the pipeline is early-stage and unproven.
Key events, in time order
None yet
None yet
A user highlights Creative Medical Technology ($CELZ) advertising on CNBC despite its small market cap, questioning the network's role in promoting such companies.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
